Abrocitinib Treatment of Atopic Dermatitis or Eczema in Patients with Coexistent or Prior Psoriasis: Three Cases with Literature Review
Abstract
Purpose: To characterize clinical outcomes of abrocitinib in patients with coexistent psoriasis and atopic dermatitis (AD)/eczema and to synthesize published case-level evidence on Janus kinase (JAK) inhibitors and other biologic strategies for this overlap phenotype.
Patients and methods: We retrospectively reviewed three adults with psoriasis and concurrent eczema/AD-like dermatitis treated with abrocitinib, with outcomes assessed using PASI, SCORAD/IGA, and PP-NRS. A structured search of MEDLINE, Embase, and Web of Science (inception to 31 December 2025) identified eligible reports describing clinically diagnosed psoriasis-eczema/AD overlap treated with JAK inhibitors or biologic agents, with independent screening and de-duplication.
Results: Two patients receiving abrocitinib 100 mg/day achieved marked improvement, and one patient refractory to upadacitinib 30 mg/day improved after switching to abrocitinib 200 mg/day; no treatment-related adverse events were observed, and one patient had no recurrence during >4 months of follow-up. In the literature synthesis, 16 JAK inhibitor-treated cases (abrocitinib, upadacitinib, baricitinib) showed consistent clinical benefit, with PASI decreasing from 9-25.9 to 0-3.2 and SCORAD/EASI decreasing from 24.6-71.1 to 0-30.4, and no adverse events reported. Nine cases treated with other biologics also improved (PASI 9.1-35 to 3-7.2; SCORAD/EASI 19.4-59 to 0-9.4), with conjunctivitis reported in one dual-biologic case.
Conclusion:…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.